OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

            Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens

OpGen Provides Curetis Group Business Update and Announces Completion of Key Milestones in Planned Business Combination

GAITHERSBURG, Md., Nov.  19, 2019  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the Center for Disease Control (CDC) has released updated data increasing the number of deaths in the United States (U.S.) from antibiotic-resistant bacteria and fungi, and highlighting the continuing threat of rising antibiotic resistance.  According to the CDC , these pathogens cause more than 2.8 million infections and 35,000 deaths in the U.S. each year. That means, on average, someone in the United States gets an antibiotic-resistant infection every 11 seconds, and every 15 minutes, someone dies1.  OpGen’s products have been developed to help combat these growing threats. The Acuitas® AMR Gene Panel test, currently in development, is designed to help identify drug-resistant pathogens directly from urine as an aid in the diagnosis of urinary tract infections in under three hours. The Acuitas® Lighthouse Software, also in development, is currently being tested in a state-wide initiative to help quickly identify and track urgent threat pathogens.

OpGen Products in Development to Address “Urgent Threat” Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats

OpGen, Inc. (OPGN) CEO Evan Jones on Q3 2019 Results - Earnings Call Transcript

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -28.46% and -28.00%, respectively, for the quarter ended September 2019.

OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates

GAITHERSBURG, Md., Nov.  04, 2019  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On October 28, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”) has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST).

OpGen Provides Update on Curetis Group Company Ares Genetics Business

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week?

GAITHERSBURG, Md., Oct.  28, 2019  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the closing of its previously announced underwritten public offering of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit, raising gross proceeds of approximately $9.4 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriter a 30-day option to purchase up to an additional 705,000 shares of common stock and/or common warrants to purchase up to 705,000 shares of common stock.

OpGen Announces Closing of $9.4 Million Underwritten Public Offering

GAITHERSBURG, Md., Oct.  23, 2019  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of $2.00 per unit. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. OpGen expects to receive aggregate gross proceeds of $9.4 million from the offering, prior to deducting underwriting discounts and commissions and other estimated offering expenses. OpGen has granted the underwriter a 30-day option to purchase up to an additional 705,000 shares of common stock and/or common warrants to purchase up to 705,000 shares of common stock.

OpGen Announces Pricing of $9.4 Million Underwritten Offering

GAITHERSBURG, Md., Oct.  23, 2019  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent covering the Lighthouse Profiling technology used in the company’s software for tracking antimicrobial resistant pathogens. Patent application US 20160085912A1 “Systems, Apparatus, and Methods for Generating and Analyzing Resistome Profiles” covers the use of the company’s Acuitas Lighthouse® Software for real-time monitoring of superbug infections and other multi-drug resistant infections. The final patent is expected to be issued in the coming weeks.

U.S. Patent Allowed Covering Acuitas Lighthouse® Software

As showcased at IDWeek 2019 - Test results show parity with urine culture and whole genome sequencing results As showcased at IDWeek 2019 - Test results show parity with urine culture and whole genome sequencing results

OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections

Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software to be highlighted in a conference speaker session Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software to be highlighted in a conference speaker session

OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019

GAITHERSBURG, Md., Sept.  18, 2019  (GLOBE NEWSWIRE) --  OpGen, Inc . (Nasdaq: OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen.  On September 16, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”) has entered into a multi-phase collaboration with an undisclosed leading global in vitro diagnostics corporation to jointly develop diagnostic solutions for infectious disease testing based on next-generation sequencing (“NGS”) technology. The companies signed an R&D and option agreement for the first phase of the collaboration.

OpGen Provides update on Curetis Group’s R&D Collaboration

In a health care deal announced Wednesday, OpGen Inc (NASDAQ: OPGN) said it will acquire German molecular diagnostics company Curetis.

OpGen To Merge With German Molecular Diagnostics Company Curetis In $24M Deal

Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.

Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

OpGen, Inc. (OPGN) CEO Evan Jones on Q1 2019 Results - Earnings Call Transcript

Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings?

News for OpGen Stock (OPGN)